During a comprehensive annual wellness exam, an asymptomatic postmenopausal patient discusses her current osteoporosis regimen. She has been strictly adherent to weekly oral alendronate for the past 5 years. She has remained physically active and reports no history of clinical fractures, bone pain, or loss of height. A dual-energy x-ray absorptiometry (DEXA) scan obtained prior to this visit reveals a femoral neck T-score of , indicating stability compared to her prior assessments. Her renal function and serum calcium levels are normal.
Based on current clinical guidelines, arrange the following management and monitoring steps in the most appropriate chronological sequence for this patient's ongoing care.
- 1Calculate the updated major osteoporotic fracture risk using a validated clinical assessment tool.
- 2Discontinue the oral alendronate prescription to initiate a therapeutic drug holiday.
- 3Perform annual clinical evaluations to screen for subtle height loss or new back pain.
- 4Order a subsequent dual-energy x-ray absorptiometry (DEXA) scan in to years.
Cevap
The correct chronological sequence is to first calculate the updated fracture risk, then discontinue the oral alendronate to initiate a drug holiday, follow up with annual clinical evaluations for fracture signs, and finally order a repeat DEXA scan in 2 to 4 years.
The patient has completed 5 years of oral bisphosphonate therapy and has a stable bone density without prior fractures, making her a candidate for a drug holiday. The protocol requires first formally establishing her low-to-moderate risk profile. Once confirmed, the alendronate is discontinued to reduce the risk of adverse events like atypical femur fractures. Monitoring then transitions to annual clinical checks for height loss or new bone pain, followed by a repeat DEXA scan in 2 to 4 years to definitively reassess the need for treatment resumption.
Adım Adım Çözüm
Anahtar Kavram
The management of osteoporosis in low-to-moderate risk patients involves initiating a bisphosphonate drug holiday after 5 years of oral therapy, followed by sequential clinical monitoring annually and densitometric monitoring every 2 to 4 years.